Mechanism, pharmacokinetics, and what the trials actually measured.

What this research page covers

This page is a close reading of the sermorelin science: how the molecule works at the GHRH receptor on pituitary cells (the mechanism), how quickly it leaves the body (about 11 to 12 minutes in plasma — one of the shortest half-lives of any studied peptide), what the pivotal pediatric trials demonstrated, what the small adult investigational studies measured, and how a structurally related compound called tesamorelin provided class-validating evidence.

A key point throughout: sermorelin does not supply growth hormone directly. It asks the pituitary to release its own stored hormone. Because the pituitary's natural brake system (somatostatin) remains intact, the resulting growth-hormone profile is pulsatile rather than flat — a structural difference from direct growth-hormone replacement that recurs in every mechanistic discussion.

Receptor pharmacology

Sermorelin is a GHRH receptor (GHRHR) agonist. The receptor sits on the surface of somatotroph cells in the anterior pituitary, where it couples to the Gs heterotrimeric G-protein and elevates intracellular cAMP through adenylyl cyclase activation; PKA phosphorylates downstream substrates that drive GH gene transcription and the release of stored GH from secretory granules. A parallel MAPK arm contributes to somatotroph proliferation and gene-expression maintenance ^[12].

The physiologic significance of binding GHRHR rather than the GH receptor directly is structural. Recombinant human GH (somatropin) bypasses the pituitary entirely and presents a relatively flat exogenous exposure profile. Sermorelin works upstream: it asks the pituitary to release its own pulse, and because the pituitary's somatostatin negative-feedback loop remains intact, the resulting GH profile is pulsatile and physiologically constrained. Walker's 2006 review framed this as the central mechanistic advantage of GHRH-class stimulation over direct GH replacement — preservation of the somatotrophic axis rather than its bypass, with reduced risk of supraphysiologic IGF-1 and minimized tachyphylaxis ^[9].

There are also direct, GH-independent actions. The 2025 review of hypothalamic GHRH summarized evidence that GHRH activates sleep-regulatory neurons in the preoptic hypothalamus, augmenting NREM sleep duration and slow-wave EEG power independent of the pituitary GH response ^[12]. Preclinical cardiac models have reported direct cardioprotective effects of GHRH agonists in rodent ischemia-reperfusion and pressure-overload models, with reduced infarct size, preserved left-ventricular function, and attenuated pathologic hypertrophy ^[11]. A 2021 high-throughput screen of transcriptomic data from 1,018 glioma patients also identified sermorelin as a candidate for recurrent glioma, with dose- and time-dependent inhibition of glioma cell growth in vitro via cell-cycle arrest and immune-checkpoint downregulation ^[10].

Pharmacokinetics

The pharmacokinetic profile is one of the most quoted facts about sermorelin and one of the most consequential for how it has been studied.

In 12 normal adult volunteers studied at 0.25 to 1.0 mg intravenous and 2 mg subcutaneous, the plasma half-life was approximately 11 to 12 minutes, with mean clearance of 2.4 to 2.8 L/min; subcutaneous absolute bioavailability was approximately 6 percent, and peak plasma concentration occurred between 5 and 20 minutes ^[5]. Degradation proceeds via dipeptidyl peptidase-4 (DPP-4) cleavage of the N-terminal Tyr-Ala dipeptide — the same protease implicated in incretin metabolism — and neutral endopeptidase (NEP) cleavage further along the chain. Less than 5 percent of administered sermorelin remains circulating at 60 minutes.

The downstream signal persists longer than the parent compound. The induced GH pulse continues for hours after sermorelin has cleared, and the hepatic IGF-1 response is measured in days rather than minutes. This dissociation — brief peptide exposure, longer-lasting biological response — is part of what motivated the once-nightly dosing schedule used across both the pediatric pivotal program and the adult investigational studies, timed to coincide with the natural early-slow-wave-sleep GH burst.

It is also the structural reason a second generation of GHRH analogs exists. Tesamorelin, the trans-3-hexenoic acid stabilized full-length GHRH analog, extends the half-life to approximately 26 minutes and was developed precisely to provide more sustained GHRHR engagement than sermorelin's roughly twelve-minute window ^[16].

The pediatric pivotal record

The clinical program that brought sermorelin to FDA approval was pediatric. Two trials anchor the record.

The Kirk study published in Clinical Endocrinology in 1994 enrolled 17 prepubertal children with idiopathic short stature, aged 4.3 to 11.0 years, and administered GHRH(1-29)NH2 at 20 mcg/kg subcutaneously twice daily for 12 months. Mean height velocity increased from 4.8 cm per year pre-treatment to 7.2 cm per year on therapy (p=0.001), with an average 3.4 cm improvement in final-height prediction; the effect waned within 12 months of treatment cessation ^[2].

The pivotal multicenter International Study Group trial enrolled 110 prepubertal GH-deficient children and demonstrated sustained efficacy of subcutaneous sermorelin acetate over 36 months of treatment, dosed once daily at bedtime ^[15]. The labeled regimen that emerged from this program was 30 mcg/kg subcutaneous once nightly. Catch-up growth was observed in the majority of GH-deficient children, though the height-velocity response was modestly inferior to once-daily 30 mcg/kg somatropin in head-to-head pediatric comparisons — the observation that ultimately shaped the commercial decision to discontinue the branded product ^[1].

The adult investigational record

The adult investigational literature is smaller than the pediatric record and more recent in clinical interest. Three studies are foundational.

The Khorram trial, published in the Journal of Clinical Endocrinology & Metabolism in 1997, was a single-blind randomized controlled study of nightly subcutaneous GHRH(1-29) at 10 mcg/kg in 19 men and women aged 55 to 71, over 16 weeks. The reported outcomes included a significant rise in nocturnal GH and IGF-1, a mean 1.26 kg increase in lean body mass in men, improved insulin sensitivity, and patient-reported improvements in well-being and libido ^[6].

The Vitiello group's six-month nightly subcutaneous sermorelin program in healthy older men and women, funded under NIH grants R01 AG10943 and R01-MH53575, used 14 mcg/kg (approximately a 1 mg evening dose) and reported a doubling of 24-hour GH secretion, an approximately 40 percent rise in IGF-1, a roughly 5 percent reduction in body fat with reciprocal lean-mass increase in men and non-estrogen-replaced women, and a 5-to-7 percent improvement in cognitive processing speed ^[8]. Estrogen replacement was reported to blunt the body-composition response.

The class-validating Baker trial in Archives of Neurology in 2012 randomized 152 adults aged 55 to 87 — 66 with mild cognitive impairment — to 20 weeks of daily 1 mg subcutaneous tesamorelin or placebo. Executive function improved significantly (p=0.005), IGF-1 rose by 117 percent within the physiologic range, and body fat decreased by 7.4 percent (p<0.001); cognitive benefit was comparable between participants with mild cognitive impairment and healthy older adults ^[7]. The closely related stabilized GHRH analog was also evaluated for HIV-associated visceral adiposity in the Falutz trial published in the New England Journal of Medicine in 2007, where 26 weeks of daily 2 mg subcutaneous administration produced approximately 15 percent reduction in visceral adipose tissue and a 50 to 100 percent rise in IGF-1 ^[16].

The reported safety profile

Across pediatric pivotal trials and adult investigational studies, the reported adverse-event profile for sermorelin has been mild and predominantly local. Transient facial flushing and injection-site reactions — pain, erythema, swelling — were observed in approximately one in six patients, with occasional headache; serious adverse events were rare, and no clinically significant changes in routine laboratory values were reported ^[14].

Documented contraindications include active malignancy, pregnancy, untreated severe hypothyroidism, and hypersensitivity to sermorelin or any vial component. The World Anti-Doping Agency prohibits GHRH and its analogs, including sermorelin, under Code section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) for in- and out-of-competition athletes.